Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM trial of metformin-related alterations in faecal flora
NL-OMON21550Not yet recruiting
- Sponsor
- Academic Medical Centre PO Box 22660 1100 DD Amsterdam Netherlands
- Start
- Jun 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of metformin and insulin glargine in type 2 diabetes mellitus (T2DM) and impaired fasting glucose (IFG) (2 arms), sponsored by Academic Medical Centre PO Box 22660 1100 DD Amsterdam Netherlands. Primary endpoint: Changes in faecal flora after 15 weeks. Planned start Jun 2009; status: not yet recruiting.
02
Drugs
metformininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)impaired fasting glucose (IFG)
Beyond the preview
Go deeper on NL-OMON21550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21550.